Buchang Pharmaceutical announced that the company recently received the Drug Registration Certificate for Atomoxetine Hydrochloride Oral Solution issued by the National Medical Products Administration. The drug is used to treat attention deficit hyperactivity disorder in children and adolescents aged 6 years and older. As of September 30, 2026, the company's research and development expenses invested in this project amounted to approximately 13.72 million yuan. The company stated that obtaining the drug registration certificate this time is conducive to optimizing the product structure and will have a positive impact on future operations.
Shandong Buchang Pharmaceuticals Co LtdReceived Drug Registration Certificate for Atomoxetine Hydrochloride Oral Solution, a new ADHD product approval that optimizes its product structure.
